The Group’s serum-free iterative rabies vaccine has been accepted for market registration by the National Medical Products Administration (NMPA), with the Acceptance Notice (《受理通知書》) (No. CXSS2500044). In addition, AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (艾美榮譽(寧波)生物製藥有限公司), a wholly-owned subsidiary of the Group, has recently obtained the relevant production license for the iterative serum-free rabies vaccine.

The clinical trial approval for the mRNA herpes zoster vaccine has been recently received from the U.S. Food and Drug Administration (“FDA”). This is the second innovative vaccine product of the Group approved by the U.S. FDA for clinical trials, following the mRNA RSV vaccine, which marks a new milestone in the Group’s globalization strategy.

The Group is expected to record an unaudited revenue ranging from RMB1.25 billion to RMB1.3 billion for the Reporting Period, representing an increase ranging from RMB60 million to RMB110 million or 5% to 9% as compared to the revenue of RMB1.19 billion for the previous year; and the Group is expected to record an unaudited net loss ranging from RMB250 million to RMB290 million, representing a significant decrease in loss ranging from RMB1.66 billion to RMB1.7 billion or 85% to 87% as compared to the net loss of RMB1.95 billion in the previous year.

AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd. (艾美榮譽(寧波)生物製藥有限公司), a wholly-owned subsidiary of the Group, has recently obtained the production license for the iterative serum-free rabies vaccine, and will submit an application for drug marketing registration. At present, there is no serum free rabies vaccine that has been approved for launch in the global market, and this product is expected to be the first one on the market, marking a major technological breakthrough for the Group and further cementing the Group’s leading position in the global rabies vaccine industry.

The clinical trial approval for the human diploid rabies vaccine developed by the Group has been recently obtained from the National Medical Products Administration. This product, as an iterative upgraded human diploid rabies vaccine, is featured with super highly-effective characteristics, and also marks a significant iterative upgrading in technology for the global rabies vaccine industry. Results from animal testing show that the Group’s human diploid rabies vaccine triggers a high level of antibodies that provide sufficient protection after immunization. Under the same dosage, the potency of the Group’s human diploid rabies vaccine is significantly higher than that of those marketed human diploid rabies vaccines.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA respiratory syncytial virus vaccines has been approved by the U.S. Food and Drug Administration (“FDA”) recently, which is the first approval from FDA for the Group’s products and marks a significant progress for the Group’s internationalization strategy.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA shingles/ herpes zoster vaccines has been submitted to the U.S. Food and Drug Administration (“FDA”) recently, marking a new advancement in the Group’s global strategy.

As a leading vaccine enterprise in China, the Group actively responds to the national “AI +” industrial development strategy, fully deploys and integrates DeepSeek, and promotes the application of the DeepSeek R1 version in all business scenarios of the Group through a localization strategy. This aims to achieve “cost reduction, quality improvement and efficiency enhancement” throughout the entire lifecycle of vaccines.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of the mRNA shingles/ herpes zoster vaccines developed by the Group has been submitted to the Center for Drug Evaluation (CDE) of National Medical Products Administration of China recently.